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Abstract: Workout capacity is energy-production driven. To produce peak metabolic power outputs,
the organism predominantly relies more on anaerobic metabolism, but this undoubtedly has
a negative and limiting impact on muscle function and performance. The aim of the study was
to evaluate if an innovative polyphenol-based food supplement, PerfLoad®, was able to improve
metabolic homeostasis and physical performance during high-intensity exercises under anaerobic
conditions. The effect of a supplementation has been investigated on fifteen recreationally-active
male athletes during a randomized, double-blind and crossover clinical investigation. The Wingate
test, an inducer of an unbalanced metabolism associated to oxidative stress, was used to assess
maximum anaerobic power during a high-intensity exercise on a cycle ergometer. Supplementation
with PerfLoad® correlated with a significant increase in total power output (5%), maximal peak
power output (3.7%), and average power developed (5%), without inducing more fatigue or greater
heart rate. Instead, oxidative homeostasis was stabilized in supplemented subjects. Such results
demonstrated that PerfLoad® is a natural and efficient solution capable of, similarly to training
benefits, helping athletes to improve their physical performance, while balancing their metabolism
and reducing exercise-induced oxidative stress.
Keywords: preworkout; anaerobic power; pulse pressure; oxidative stress; Wingate test
1. Introduction
Workout capacity is determined by the ability to synchronise interactions between the
cardiovascular, respiratory, skeletal-muscular, and nervous systems [1]. Additionally, the characteristics
of the exercise predominantly dictate the preferred metabolic pathway used to yield sufficient energy
and, consequently, affect overall performance. Energy production is both time- and intensity-related,
depending on the energy system involved: phosphagenic (high intensity and short duration),
glycolytic (moderate intensity and short duration), or oxidative (low intensity and long duration) [2,3].
Accordingly, when high peak metabolic power outputs are to be achieved, the organism predominately
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relies more on anaerobic metabolism; as an adaptive response, the exerting muscles prioritise two
pathways of stored energy, both accessible without oxygen: the phosphagen system and anaerobic
glycolysis. Such anaerobic functioning produces energy more rapidly, but this is at the cost of increased
accumulation of unfavourable end-products, mainly lactate and reactive oxygen species, which may
have a negative and limiting impact on muscle function and performance [4]. High-intensity training
is commonly used to help reduce the production of fatigue-associated metabolites, increase better
metabolic buffering [5–7], as well as lower the neuromuscular fatigue [8]. In addition, it improves both
aerobic and anaerobic systems [9]. Working at high-intensity levels also challenges the organism’s
capability to minimize oxidative stress [10].
Pre-workout supplementation has become a significant nutritional approach in recent years.
Several bioactive components [11–13] may have a positive effect on metabolic activity, which benefits
strength and power and overall performance during physical exercise. PerfLoad® is an innovative food
supplement, composed of polyphenols, which has been designed to improve metabolic homeostasis
during high-intensity exercises. Although some studies have examined the effect of polyphenols on
blood flow [14–17], it is not known how polyphenols may affect physical performance, cardiovascular,
and metabolic responses during high-intensity activities.
Therefore, the aim of the present clinical study was to investigate whether supplementation with
PerfLoad® could improve physical performance during high-intensity physical exercise in anaerobic
conditions while sustaining physiological and biochemical processes of recreationally-active athletes.
2. Materials and Methods
2.1. Ethics Statement
The protocol of the study was approved by the Ethics Committee at the Catholic University of
Murcia on 30 October 2015, protocol number CFE-PERFLOAD-58/15, and conducted according to
the guidelines laid down in the Declaration of Helsinki [18] and in compliance with good clinical
practices defined in ICH Harmonized Tripartite Guidelines [19]. All participants were informed about
the operating procedures of the clinical trial and they agreed to sign a written informed consent form
before entering the study.
2.2. Study Population
Twenty healthy recreationally-active (i.e., not performing more than three days of
moderate-intensity activity per week) male volunteers in comparable physical condition, a minimum
of 20 years old, were recruited through advertisements in Murcia, Spain. Any individuals usually
involved in high-intensity training or with a history of cardiorespiratory problems or chronic illness
were not enrolled. In addition, individuals with a history of orthopaedic injury or surgery within the
past year or any physical condition considered a contraindication to the type of exercise performed
in the study were excluded. Additionally, those affected by any medical condition or using any
medication, nutritional product, dietary supplement, or program which might interfere with the
conduct of the study or place the subject at risk, were not included. Furthermore, individuals could
not participate if they had any food allergy to grape, green tea, pomegranate, or corn.
2.3. Test Supplement
PerfLoad®, supplied by FYTEXIA (France), is principally obtained by alcohol and water extraction
of grape (Vitis vinifera L.) and pomegranate (Punica granatum L.), and by water extraction of green
tea (Camellia sinensis L. Kuntze). PerfLoad® provides bioactive compounds, especially polyphenols,
from flavonoid, ellagitannin, and stilbenoid families, and natural components of the methylxanthine
family. PerfLoad® complies with regulations on food contaminants and on banned and prohibited
substances. The placebo product was 100% maltodextrin, which is polyphenol- and methylxanthine-free.
Both PerfLoad® and the placebo were supplied in 500-mg capsules of identical appearance and flavour.
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The supplement was analysed by means of high-peformance liquid chromatography (HPLC).
An Agilent HPLC 1260 apparatus (Singapore) (Openlab CDS chemstation edition software (Santa Clara,
CA, USA) was used) coupled with a diode array detector was used. Separations were carried out by
means of a Zorbax Stablebond SB-C18 column (4.6 × 2 mm; 5 µm particle size; New Port, DE, USA).
To detect different phenolic classes, two different analytical methods were adopted: one for bioflavonoids
and trans-resveratrol and one for punicalagins. Data analyses were performed as described below.
For bioflavnonoids and trans-resveratrol, mobile phase A consisted of 6% acetic acid, mobile phase
B was 5% acetic acid and 30% acetonitrile, and mobile phase C was 100% acetonitrile. The program
was as follows: (a) 5 min 100% A; (b) 5 to 10 min linear gradient from 0% to 40% B; (c) 10 to 15 min
linear gradient from 40% to 60% B; (d) 15 to 20 min linear gradient from 60% to 75% B; (e) 20 to 25 min
linear gradient from 75% to 90% B; (f) 25 to 30 min linear gradient from 90% to 100% B; (g) 30 to 35 min
linear gradient from 0% to 100% C; (h) 35 to 40 min 100% C; (i) 40 to 45 min linear gradient from 0% to
100% A. Simultaneous monitoring was performed at 280 and 310 nm at a flow rate of 1 mL/min and
an injection volume of 25 µL.
For punicalagins, the mobile phase consisted of 0.1% orthophosphoric acid and mobile phase C
was 100% methanol. The program was as follows: (a) 0 to 15 min linear gradient from 5% to 10% B;
(b) 15 to 30 min linear gradient from 10% to 30% B. Monitoring was performed at 260 nm at a flow rate
of 0.8 mL/min and an injection volume of 5 µL.
Bioflavonoids, punicalagins, trans-resveratrol, and caffeine were respectively determined as
catechin at 280 nm, punicalagins at 260 nm, trans-resveratrol at 310 nm, and caffeine at 280 nm.
2.4. Study Design
The study was a randomized, double-blind, cross-over and placebo-controlled pilot clinical trial.
Seven days prior to the supplementation period, volunteers underwent familiarization with the exercise
protocol. Following inclusion, they were randomly assigned, using a random allocation sequence
generated by a computerized random number generator, to one of two groups. At day one of the
investigation, subjects received their supplementation and were instructed to ingest, acutely, 1000
mg of the supplement in two 500-mg capsules of either PerfLoad® or placebo, in the presence of the
investigator 60 min before the start of the exercise protocol. Simultaneously, they received a standardized
and polyphenol- and antioxidant-free breakfast consisting of a ham and cheese sandwich, six “Maria”
cookies, and one glass of water. After a five-week wash-out period, each volunteer was switched to the
other supplementation group for a second investigation period. On days without exercise, volunteers
were instructed to continue practicing their usual physical recreational activities.
2.5. Exercise Protocol
The exercise protocol consisted of 4 × 30-s bouts of cycling (Wingate test; WAnT) at all-out
intensity, which was performed on a cycle ergometer (Monark Ergomedic 894E Peak Bike, Vansbro,
Sweden). For every bout, the breaking force was constant and individualized for each volunteer,
corresponding to 7.5% of the body mass. Prior to the first repetition, a 5-min standard warm-up
protocol was performed followed by a 1-min passive recovery period [20]. The rest period between
the first and second sprints and between the third and fourth was 4 min long. Between the second and
third sprints, the recovery period lasted for 5 min.
2.6. Primary Outcome
The primary outcome was the anaerobic mechanical power production performed at
an “all-out” pace (i.e., maximal) during the first 30-s sprint. Anaerobic peak power (PP: highest
anaerobic mechanical power generated within 30-s bout), total anaerobic work capacity (TAWC),
anaerobic average power (AP), and anaerobic fatigue index (FI: percentage of decline in power) were
also determined for the first bout. The second, third, and fourth sprints were performed with the aim
of inducing greater oxidative stress [21,22].
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2.7. Secondary Outcome
On the testing days, secondary outcomes were monitored at different points. In the pre-test
period, both blood pulse pressure and heparinized blood samples were measured and analysed 60 min
before the volunteers performed the exercise protocol. These procedures were then repeated (i) just
before the start of the first sprint; (ii) following the completion of the fourth bout; and (iii) again in the
recovery period, 60 min after subjects completed the last sprint. Heart rate was taken 30 s after the end
of the Wingate test. The average heart rate from the post-30 s–60 s time interval was calculated.
Similarly, both total circulating antioxidant defences and total circulating antioxidant reserves
were monitored in fresh heparinized blood using the KRL (Kit Radicaux Libres) [23–28] and RESEDA
(RESErves Défenses Antioxydantes) tests (Spiral Laboratories, 21560 Couternon, France). The KRL
test [29,30] allows the dynamic evaluation of the overall antioxidant defense potential of an individual.
The RESEDA test [31] is based on the same principle with a step of releasing biologically active and
potentially antioxidant molecules in reserve as: R1 (glucosides), R2 (sulphates), and R3 (glucuronides).
Similarly, lactate dehydrogenase (LDH) was measured using a colorimetric commercial kit
(ab102526, Abcam, Cambridge, MA, USA) to both confirm exercise-induced haemolysis of red
blood cells and to evaluate supplement protection. Finally, frozen (stored at −80 ◦C) blood samples
were analysed for specific antioxidant enzymes. Activities of superoxide dismutase (SOD) and
glutathione peroxidase (GSH-PX) were performed in plasma samples using colorimetric commercial
kits (respectively, ab65354 and ab102530 kits, Abcam, Cambridge, MA, USA), and the activity of
catalase was performed in haemolysed erythrocytes using a colorimetric commercial kit (ab83464,
Abcam, Cambridge, MA, USA).
2.8. Statistical Analysis
Datasets were analysed using Statview software version 4.51.1 (Abacus Concepts, Berkeley, CA,
USA). The data are expressed as mean ± standard deviation (SD). Changes within and between
groups during the length of the studied period of the crossover protocol were analyzed using a paired
Student’s t-test. Statistical significance was set at p < 0.05.
3. Results
3.1. Characterisation of the Phenolic Profile of the Supplement
The total bioactive content was measured to correspond to 41 g/100 g dry matter. Bioflavonoid
content was measured at 17 g/100 g, punicalagin content was measured at 10 g/100 g, caffeine content
was measured at 12 g/100 g, and trans-resveratrol content was measured at 2 g/100 g (Figure 1).
For a 1000 mg dose, it corresponds to 410 mg of ingested bioactives, i.e., 290 mg of various polyphenolic
bioactives and 120 mg of caffeine (Table 1).
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Table 1. Bioactive content for a 1000-mg daily dose of the supplement.
Bioactive Dose
Total polyphenols 290 mg
Bioflavonoids 170 mg
Punicalagins 100 mg
Trans-resveratrol 20 mg
Caffeine 120 mg
3.2. Participant Characteristics
Twenty-three volunteers were assessed for eligibility and three of them did not meet the inclusion
criteria and were excluded from participation in the study. Among the twenty volunteers recruited in
the study, four did not report to the Research Center for personal reasons and one did not complete
the exercise protocol due to conflict with their study schedule (Figure 2).
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study intervention.
Fifteen participants completed the entire protocol and were included in the analysis.
Baseline anthropometric characteristics of volunteers are summarized in Table 2.
Table 2. Baseline participant characteristics.
Characteristics All Volunteers
N 15
Age (years, mean ± SD) 22.2 ± 2.2
Height (cm, mean ± SD) 178. 4.3
Weight (kg, mean ± SD) 75.1 6.6
BMI (kg/m2, mean ± SD) 22.3 ± 1.9
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3.3. Power Production
TAWC significantly increased by 5.0% in the supplemented group compared to the placebo
population (p = 0.025), representing a production of an additional 876 Joules in 30 s group (Figure 3).
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Figure 3. Anaerobic mechanical power (W) developed during a 30-s Wingate bout and representing the
total anaerobic work capacity (J/30 s). Values are means ± SD, n = 15 (placebo) or n = 15 (PerfLoad®).
* Superscript indicates an intergroup difference between PerfLoad® and placebo, p < 0.05.
Similarly, PP of the supplemented subjects significa tly improved by 3.7% (p = 0.048), and the
production of AP was significantly enhanced by 5.0% (p = 0.025), compared to those who received the
placebo (Table 3). In both groups, no significant difference was demonstrated in the anaerobic fatigue
index, FI, with respective values of 39% and 38% (p = 0.395) for the supplement and placebo grou s
(Table 3).
Similarly, heart rate, which was measured just after the end of the exercise of power production,
revealed no significant between-group difference, with 132 a 129 beats per minute (p = 0.344)
(Table 3).
Table 3. Peak power (W) and average power (W) measured during, and fatigue i dex (%) nd hea t
rate (B M), measured just after, a 30-s WA T bout. Values are m ans ± SD, n = 15 (placebo) or n = 15
(PerfLoad®). * Superscript indicates an intergroup difference between PerfLoad® and placebo, p < 0.05.
Variables Placebo Group PerfLoad® Group p Value
Peak power (W, mean ± SD) 734 ± 104.7 761 ± 92.1 * 0.048
Average power (W, mean ± SD) 586 ± 78.9 615 ± 75.4 * 0.025
Fatigue index (%, mean ± SD) 38 ± 12.9 39 ± 10.4 0.395
Heart rate (bpm, mean ± SD) 129 ± 15.1 132 ± 25.9 0.344
3.4. Blood Pulse Pressure
Both groups demonstrated a slight increase in blood pulse pressure (BPP) just before the start
of the first sprint (Figure 4). While the placebo group experienced an additional elevation of BPP at
the end of the exercise, supplemented subjects exhibited a decrease, reaching the basal level they had
60 min before; at 11.4 mmHg (p = 0.095), the difference between both groups represents a significant
trend. Sixty minutes after the end of the exercise, the difference between both groups was significant
at 9.3 mmHg (p = 0.034).
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Figure 4. Blood pulse pressure ( mHg) measured 60 min before and just before (Pre-exercise),
just before and just after (Exercise), just after and 60 min after (Post-exercise) a 30-s Wingate bout.
Values are means ± SD, n = 15 (placebo) or n = 15 (PerfLoad®). * Superscript indicates an intergroup
difference between PerfLoad® and placebo, p < 0.05.
3.5. Protection of Red Blood Cells
The KRL and RESEDA test assays revealed that while the KRL level for subjects in the placebo
group significantly increased by 10.2% (p = 0.021) during the 60-min period of pre-exercise, a respective
decrease of 0.6% (p = 0.437) within the supplemented population for the same period demonstrated
the absence of any significant change in the KRL level for the group (Figure 5).
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Applying the test to blood samples taken immediately after the exercise period, a significant
6.1% (p = 0.040) decrease in KRL level was found within the placebo group, whereas an opposite
trend seemed to be experienced by the volunteers who received the supplement with a 6% (p = 0.121)
increase in this marker of protection. Finally, during the recovery period, the KRL protection values
for individuals who received the placebo continued to decline by 2.1% and nearly reached their basal
level, while the values in those supplemented with PerfLoad® continued to enrich by 2.6% to reach
a strong increasing trend of 8.2% compared to their basal level (p = 0.084).
3.6. Antioxidant Enzymes and LDH
During the exercise period, SOD activity remained stable within the placebo group, but started to
rapidly weaken by 4.3% during the recovery period (Figure 6A). In parallel tests, immediately after the
first sprint, the value of plasmatic SOD in subjects supplemented increased by 18.7% and stabilized at
14.1% at the end of the recovery period. With a value of 20.3%, the difference in SOD activity between
the groups after 60 min of recovery was significant (p = 0.043).
Similarly, with a decrease of 0.9%, GSH-PX activity measured immediately after the exercise
period within the placebo group demonstrated no change, but started to decrease during the recovery
phase (Figure 6B). At the same time, GSH-PX activity in supplemented volunteers increased by
11.1% just after the resistance workload, and remained stable until the end of the recovery period.
The difference in GSH-PX activity reached among both groups was established at 17.9% (p = 0.106).
With respect to catalase, the scenario was quite similar. Within the placebo population, the enzyme
activity slightly decreased by 3.6% consecutively with the power production exercise, and stabilized
thereafter (Figure 6C). Among supplemented subjects, the enzyme increased by 11.9% after the physical
exercise and stabilized until the end of the recovery period. Thus, at the end of the exercise period,
the difference of variation between both groups reached 15.5% (p = 0.047), which almost stabilized
until the recovery period with a strong trend of a difference of 12.4% (p = 0.085).
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Figure 6. SOD (A), GSH-PX (B), Cat (C), and LDH (D) activities measured just before (Pre-exercise), 
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Figure 6. SOD (A), GSH-PX (B), Cat (C), and LDH (D) activities measured just before (Pre-exercise),
just after (Exercise), and 60 min after (Post-exercise) a 30-s Wingate bout. Values are means ± SD,
n = 15 (placebo) or n = 15 (PerfLoad®). * Superscript indicates an intergroup difference between
PerfLoad® and placebo, p < 0.05.
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Finally, regarding LDH released in the plasma, a significant increase of 59.2% (p = 0.016) was found
in the placebo-supplemented group just at the end of the exercise protocol, while no modification in
LDH levels during the same period was evident in supplemented subjects (Figure 6D). At the end of
the recovery period, LDH of the placebo group returned to basal levels.
4. Discussion
There are several physiological factors that limit performance during a 30-s WAnT.
Extremely intense sprint exercise cannot be sustained for longer than 60 s due to the bioenergetics of
all-out efforts [32]. In the course of our investigation, we demonstrated that volunteers supplemented
with PerfLoad® were able to increase their TAWC by 5.0%, corresponding to an overproduction of
876 Joules in 30 s. Their PP production improved by 27 Watts, which represents a significant increase in
power output. Finally, the AP produced was enhanced by 29 Watts/s, demonstrating that the significant
improvement of power production is sustainable during the whole time of the exercise. To reach
comparable performances, athletes usually have to undergo very specific physical training and/or be
supplemented with synthetic aids [12,13]. This was confirmed in cycling athletes who were trained
for a six-week period to gain 600 Joules of production [33]. In another study, volunteers subjected to
a 30-s high-intensity exercise and supplemented with creatine phosphate, experienced only a slight
increase in workload of 3.2% compared to the placebo group [34]. Thus, PerfLoad® supplementation
is apparently able to rapidly and significantly increase performance during an intense anaerobic
effort. Since such results have not been previously described by the support provided by one of its
single ingredients alone at a similar dose, the benefits of supplementation are possibly associated
to synergistic formulation. In the example of caffeine, despite the fact that it is often referred to as
a nutritional ergogenic aid, many researchers have demonstrated that the methylxanthine compound,
at low to moderate levels (<5 mg/kg BW), fails to improve performance during WAnT [35–37].
Another particularly interesting endpoint observed, despite the higher power outputs developed
with the supplement, is that fatigability and heart workload were, nevertheless, not affected more
than with the placebo. Regarding the latter, it was even demonstrated that the supplementation could
provide greater protection to the heart from increased workload. Indeed, despite a similar increase
in heart rate during intense exercise-induced stress in both groups, when one considers the blood
pulse pressure, a strong biomarker for heart workload [38–40], after supplementation the circulatory
system required less strength (−11.4 mmHg), which probably spared tissues more from heart shear
stress. Moreover, this was sustainable during the 60-min recovery period with a−9.3 mmHg difference
compared to the placebo group. One possible explanation is a significant decrease in vessel resistance
within the supplemented group. Indeed, several authors demonstrated the capacity of polyphenolic
compounds for improving endothelial function [41]. Notably, green tea, grape, and pomegranate
consumption, whether short- or long-term, has been associated with improved endothelial function in
clinical trials [42–44]. The proposed main mechanisms by which polyphenols would mediate improved
flow-mediated dilation, though this was not measured in the current study, are their ability to modulate
the bioavailability of nitric oxide (NO) in the endothelium through activation of endothelial nitric
oxide synthase (eNOS), and the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase, together leading to an endothelium-dependent relaxation [45].
During exercise and muscle contraction, antioxidant stores may become depleted, leaving the
body susceptible to oxidative damages [46,47]. This was confirmed with results from KRL and RESEDA
tests within the placebo population. Despite having mobilized their antioxidant defence mechanisms
during the pre-exercise period, in the span of only 30 s, the high-intensity effort consumed all of the
freed potential, and consequently decreased as many antioxidants from the reserves [24]. As opposed
to the placebo group, subjects supplemented showed no need to mobilize more defences before
the start of performance, probably because an acute increase in those they had in circulation from
supplementation had spared those stored. These results revealed a significant improvement in the
overall antioxidant reserve at the end of the recovery period, based on an increase in the defence
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system from three different available circulating reserves (glycosides, sulphates, and glucuronides;
data not shown) associated with strengthening the main enzyme-based antioxidant defence system.
The supplement probably contributed to spare oxidative homeostasis. As previously demonstrated
here, the association between polyphenols from three different botanicals is possibly more efficient at
reducing oxidative stress than a singular polyphenol [48–50]. This reflects the complex nature of the
antioxidant defence system whereby each antioxidant is most efficient at quenching a certain type of
free radical species and, here, synergy makes sense.
Finally, another significant marker of protection from exercise-induced stress is found in
the ability of supplemented subjects to stabilize plasma levels of LDH within the healthy range,
while levels for individuals in the placebo-supplemented group significantly increased by 59.2%,
thereby demonstrating the deleterious effects of physical activity on red blood cells when athletes are
not sufficiently protected.
5. Conclusions
This prospective clinical investigation on PerfLoad® demonstrates that a natural and safe
supplement is undoubtedly able to, similarly to training benefits, help improve metabolic and
physiological pathways involved in the development of maximum metabolic power during
high-intensity exercise. Indeed, supplementation is associated with a significant increase in total
power output, maximal peak power output, and average power developed, without inducing either
more fatigue or greater heart rate. Instead, the vascular system becomes even more well-maintained
and oxidative homeostasis is stabilized. The basis for the efficiency of the supplement appears to
be the synergistic activity of bioactive natural compounds, mainly polyphenols and caffeine from
the three botanical extracts. Highlighted within an increasing body of research, it appears that
some of these polyphenols are linked to improved endothelial function. During a pivotal clinical
study to confirm our findings, further investigations will have to be conducted in attempts to
elucidate the relationship between the bioavailability of polyphenol metabolites from PerfLoad®
supplementation and flow-mediated dilation, and especially its effects on stroke volume and the
functionality of capillaries.
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